Was looking back at previous letters to shareholders and news and truly forgot how long ago some things have happened. Kind of like when a star dies and you thought it was last year but it was really 5 years ago.
Do you remember...
Jan 2014 - Results from phase 1/2 trial in muscle injury. Now 4 years later and phase 3 has yet to get stamp on trial design, let alone initiated. Why the delay? With the extraordinary results they claim, you would think it would have been started asap. And here I thought enrolment was the longest part to approval.
Aug 23, 2012 - phase 2 enrolment in IC begins. 6.5 years later, still waiting for results. But CLI should get conditional approval this year. LMBO.
Nov 14, 2007 - Pluristem competes construction on new state of the art GMP facility. It was crucial for them to build it at that time I'm sure. You know, the facility that can produce 150,000 annual doses, but has probably produced maybe a thousand. Wonder how much that has cost over the years. And don't forget the 2 years delay in product development it cost us. But don't worry, competition is miles behind.
Feb 2014 - created a steering committee on Pre-eclampsia... Wonder how much that cost and more importantly why?
And the great kicker... a paragraph from their 2015 letter to shareholders.
Pluristem continues working to establish additional business collaborations with pharmaceutical companies. The new opportunities in Europe and Japan have translated into substantial interest from potential partners who would like to work together with us in both geographic regions. We are hopeful that we will achieve additional partnership for our CLI program over the next twelve months, and are also discussing partnerships for our muscle injury program and our emerging clinical program for PLX-R18, our second product. The first planned study of PLX-R18 in humans would be a Phase I trial to be submitted later this year. More details about the program are provided below.
Substantial interest? LMBO.
But I'm fine with them. Maybe if the head of human resources had actual experience other than Elbit, they would hire people in this field. Here's her bio. Another stellar resume. Running Elbit and a biotech company probably similar right. I'm good with this.
Efrat Livne-Hadass joined Pluristem in 2007 and is responsible for all aspects of Human Resources management, including recruitment, professional training, and well-being. Prior to joining Pluristem and during the years 2001-2005, Ms. Livne-Hadass held the position of Human Resources Manager at Elbit Vision Systems, a company engaged in automatic optical inspection, located in Yokneam, Israel. While holding that position, she was involved in some major challenges and change processes which the company was going through, including managing HR in a small yet global public company. Ms. Livne-Hadass holds an Executive M.A. for Human Resources manager from the department of Labor Studies, Tel-Aviv University and a B.Sw. degree from the Haifa University, majoring in public healthcare services.
AI
